Chart, Financials, Historical Prices, Industry, Insider, Messages, Options, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 26)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
9-Feb-10New Constructs, LLCN/ACYPB: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10  View Abstract
9-Feb-10EconomicInvestorN/A"The Economy Matters" Report for CYPB: the economy's impact on CYPB's price and risk, featuring the powerful EconomicInvestor Star Rating6$15  View Abstract
9-Feb-10Pechala's ReportsLubomir PechalaCYPRESS BIOSCIENCE INC (CYPB=US) - REPORT FOR ACTIVE TRADERS4$25  View Abstract
9-Feb-10ValuEngine, Inc.N/AValuEngine Industry Report for BIOTECHNOLOGY18$49  View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotechnology & Genetics Industry Market Research and Competitive Analysis 2010569$299  View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary)71$199  View Abstract
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for CYPB13$25  View Abstract
8-Feb-10Market EdgeN/AMarket Edge Equity Research Report4$10  View Abstract
8-Feb-10PriceTarget Research, Inc.N/ACypress Bioscience has a current Overall Rating of D (Negative).7$25  View Abstract
7-Feb-10PriceTarget Research, Inc.N/ABiotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards.63$20  View Abstract
Next 16
Brokerage Reports (Showing 1 to 2 of 2)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
21-Jan-10Roth Capital Partners, Inc.Research DepartmentMorning Call Summary12$25  View Abstract
20-Jan-10Roth Capital Partners, Inc.Scott R. Henry CFA, Andrew Vaino PhDPublic Citizen highlights "known" risks with Savella5$104 Stars 4 Stars View Abstract
Independent Reports (Showing 1 to 10 of 24)
Release
Date [down]		 Contributor Author Title Pages Price More Info
9-Feb-10New Constructs, LLCN/ACYPB: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10View Abstract
9-Feb-10EconomicInvestorN/A"The Economy Matters" Report for CYPB: the economy's impact on CYPB's price and risk, featuring the powerful EconomicInvestor Star Rating6$15View Abstract
9-Feb-10Pechala's ReportsLubomir PechalaCYPRESS BIOSCIENCE INC (CYPB=US) - REPORT FOR ACTIVE TRADERS4$25View Abstract
9-Feb-10ValuEngine, Inc.N/AValuEngine Industry Report for BIOTECHNOLOGY18$49View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotechnology & Genetics Industry Market Research and Competitive Analysis 2010569$299View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary)71$199View Abstract
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for CYPB13$25View Abstract
8-Feb-10Market EdgeN/AMarket Edge Equity Research Report4$10View Abstract
8-Feb-10PriceTarget Research, Inc.N/ACypress Bioscience has a current Overall Rating of D (Negative).7$25View Abstract
7-Feb-10PriceTarget Research, Inc.N/ABiotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards.63$20View Abstract
Next 14

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.